Literature DB >> 26420962

TP53 codon 72 Arg/Arg polymorphism is associated with a higher risk for inflammatory bowel disease development.

Natalia Volodko1, Mohamed Salla1, Bertus Eksteen1, Richard N Fedorak1, Hien Q Huynh1, Shairaz Baksh1.   

Abstract

AIM: To investigate the association between tumor protein 53 (TP53) codon 72 polymorphisms and the risk for inflammatory bowel disease (IBD) development.
METHODS: Numerous genetic and epigenetic drivers have been identified for IBD including the TP53 gene. Pathogenic mutations in TP53 gene have only been reported in 50% of colorectal cancer (CRC) patients. A single nucleotide polymorphism (SNP) in the TP53 gene resulting in the presence of either arginine (Arg) or proline (Pro) or both at codon 72 was shown to alter TP53 tumor-suppressor properties. This SNP has been investigated as a risk factor for numerous cancers, including CRC. In this study we analyzed TP53 codon 72 polymorphism distribution in 461 IBD, 181 primary sclerosing cholangitis patients and 62 healthy controls. Genotyping of TP53 was performed by sequencing and restriction fragment length polymorphism analysis of genomic DNA extracted from peripheral blood.
RESULTS: The most frequent TP53 genotype in IBD patients was Arg/Arg occurring in 54%-64% of cases (and in only 32% of controls). Arg/Pro was the most prevalent genotype in controls (53%) and less common in patients (31%-40%). Pro/Pro frequency was not significantly different between controls and IBD patients.
CONCLUSION: The data suggests that the TP53 codon 72 Arg/Arg genotype is associated with increased risk for IBD development.

Entities:  

Keywords:  72 codon single nucleotide polymorphism; Colorectal cancer; Inflammatory bowel disease; Tumor protein 53; rs1042522

Mesh:

Substances:

Year:  2015        PMID: 26420962      PMCID: PMC4579882          DOI: 10.3748/wjg.v21.i36.10358

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  57 in total

1.  Winter temperature and UV are tightly linked to genetic changes in the p53 tumor suppressor pathway in Eastern Asia.

Authors:  Hong Shi; Si-jie Tan; Hua Zhong; Wenwei Hu; Arnold Levine; Chun-jie Xiao; Yi Peng; Xue-bin Qi; Wei-hua Shou; Run-lin Z Ma; Yi Li; Bing Su; Xin Lu
Journal:  Am J Hum Genet       Date:  2009-04-02       Impact factor: 11.025

2.  Molecular basis for heterogeneity of the human p53 protein.

Authors:  N Harris; E Brill; O Shohat; M Prokocimer; D Wolf; N Arai; V Rotter
Journal:  Mol Cell Biol       Date:  1986-12       Impact factor: 4.272

3.  Role of a p53 polymorphism in the development of human papillomavirus-associated cancer.

Authors:  A Storey; M Thomas; A Kalita; C Harwood; D Gardiol; F Mantovani; J Breuer; I M Leigh; G Matlashewski; L Banks
Journal:  Nature       Date:  1998-05-21       Impact factor: 49.962

Review 4.  Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development.

Authors:  Samy A Azer
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-03       Impact factor: 2.566

5.  R72P polymorphism of TP53 in ulcerative colitis patients is associated with the incidence of colectomy, use of steroids and the presence of a positive family history.

Authors:  Fatih Eren; Mustafa Akkiprik; Ozlen Atuğ; Ozgür Sönmez; Gülgün Tahan; Filiz Ozdemir; Hülya Over Hamzaoğlu; Ciğdem Ataizi Celikel; Neşe Imeryüz; Erol Avşar; Ayşe Ozer
Journal:  Pathol Oncol Res       Date:  2010-03-23       Impact factor: 3.201

6.  Differential levels of transcription of p53-regulated genes by the arginine/proline polymorphism: p53 with arginine at codon 72 favors apoptosis.

Authors:  Byeong-Seon Jeong; Wenwei Hu; Vladimir Belyi; Raul Rabadan; Arnold J Levine
Journal:  FASEB J       Date:  2009-12-17       Impact factor: 5.191

7.  P53 germ line haplotypes associated with increased risk for colorectal cancer.

Authors:  A Själander; R Birgander; L Athlin; R Stenling; J Rutegård; L Beckman; G Beckman
Journal:  Carcinogenesis       Date:  1995-07       Impact factor: 4.944

Review 8.  p53 polymorphisms: cancer implications.

Authors:  Catherine Whibley; Paul D P Pharoah; Monica Hollstein
Journal:  Nat Rev Cancer       Date:  2009-02       Impact factor: 60.716

Review 9.  DNA methylation changes in inflammatory bowel disease.

Authors:  Pantelis S Karatzas; Maria Gazouli; Michael Safioleas; Gerasimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2014

Review 10.  Inflammatory bowel disease: clinical aspects and treatments.

Authors:  Marc Fakhoury; Rebecca Negrulj; Armin Mooranian; Hani Al-Salami
Journal:  J Inflamm Res       Date:  2014-06-23
View more
  4 in total

Review 1.  The Double Role of p53 in Cancer and Autoimmunity and Its Potential as Therapeutic Target.

Authors:  Alessandra Fierabracci; Marsha Pellegrino
Journal:  Int J Mol Sci       Date:  2016-11-25       Impact factor: 5.923

2.  Effect of p53 activation through targeting MDM2/MDM4 heterodimer on T regulatory and effector cells in the peripheral blood of Type 1 diabetes patients.

Authors:  Marsha Pellegrino; Gianandrea Traversi; Andrea Arena; Marco Cappa; M Manuela Rosado; Marco Andreani; Domenico V Delfino; Fabiola Moretti; Alessandra Fierabracci
Journal:  PLoS One       Date:  2020-01-29       Impact factor: 3.240

3.  Associations of TP53 codon 72 polymorphism with complications and comorbidities in patients with type 1 diabetes.

Authors:  Bartosz Słomiński; Maria Skrzypkowska; Monika Ryba-Stanisławowska; Małgorzata Myśliwiec; Piotr Trzonkowski
Journal:  J Mol Med (Berl)       Date:  2021-01-25       Impact factor: 4.599

4.  Network Pharmacology Prediction and Molecular Docking-Based Strategy to Discover the Potential Pharmacological Mechanism of Huai Hua San Against Ulcerative Colitis.

Authors:  Jiaqin Liu; Jian Liu; Xiaoliang Tong; Weijun Peng; Shanshan Wei; Taoli Sun; Yikun Wang; Bikui Zhang; Wenqun Li
Journal:  Drug Des Devel Ther       Date:  2021-07-28       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.